Abstracts tagged "giant cell arteritis"

Abstract Number: 823 • 2017 ACR/ARHP Annual Meeting
Seasonal Variation in Giant Cell Arteritis and Polymyalgia Rheumatica Hospitalizations: Data from Nationwide Inpatient Sample
Paras Karmacharya¹, Dilli Poudel², Pragya Shrestha³, Rashmi Dhital⁴ and Raju Khanal⁴, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Internal Medicine, Reading Health System, WEST READING, PA, ³Internal medicine, Reading Health System, West Reading, PA, ⁴Internal Medicine, Reading Health System, West Reading, PA
Background/Purpose: Most studies looking at seasonal variations in giant cell arteritis (GCA) note a seasonal trend, but show disparity on timing. Concurrent peaks of GCA…
Abstract Number: 786 • 2017 ACR/ARHP Annual Meeting
Smoking As a Risk Factor for Giant Cell Arteritis: A Systematic Review and Meta-Analysis
David Brennan¹, Patompong Ungprasert², Kenneth J. Warrington² and Matthew J. Koster², ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Tobacco smoking is a well-established risk factor for the development of several autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. A similar…
Abstract Number: 892 • 2017 ACR/ARHP Annual Meeting
Health-Related Quality of Life in Patients with Giant Cell Arteritis Treated with Tocilizumab in a Randomized Controlled Phase 3 Trial
Vibeke Strand¹, Sophie Dimonaco², Katie Tuckwell², Micki Klearman³, Neil Collinson² and John H. Stone⁴, ¹Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ²Roche Products, Ltd., Welwyn Garden City, United Kingdom, ³Genentech, South San Francisco, CA, ⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Superior rates of sustained glucocorticoid (GC)–free remission were shown in patients with giant cell arteritis (GCA) treated with weekly (QW) or every-other-week (Q2W) subcutaneous…
Abstract Number: 787 • 2017 ACR/ARHP Annual Meeting
Prevalence of Relapses of Giant Cell Arteritis in Patients Treated with Corticosteroids: A Meta-Analysis
Alexandra Addario¹, Quitterie Reynaud^2,3, Maxime Samson⁴, Mathilde Francois³, Stéphane Durupt³, Francois Gueyffier¹, Michel Cucherat¹, Isabelle Durieu^2,5 and Jean-Christophe Lega^3,6, ¹Equipe Evaluation et Modélisation des Effets thérapeutiques, Lyon 1 University, Lyon, France, ²HESPER group, Lyon 1 University, Lyon, France, ³Department of Internal and Vascular Medicine, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon, France, ⁴Department of Internal Medicine and Clinical Immunolgy, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ⁵Department of Internal and Vascular, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon, France, ⁶Equipe Evaluation et Modélisation des Effets thérapeutiques, UMR CNR 5558, Lyon 1 University, Lyon, France
Background/Purpose: The relapse rate of giant cell arteritis (GCA) in the patients treated by corticosteroids (CS) varied widely in observational series and randomized trials. The…
Abstract Number: 1734 • 2017 ACR/ARHP Annual Meeting
CXCR5+ CD4 T Cells Signature Differentiates Takayasu Arteritis from Giant Cell Arteritis
Anne-Claire Desbois¹, Valentin Quiniou², Patrick Bruneval³, Nicolas Derian², Anna Maciejewski-Duval², Marlène Garrido⁴, Cloé Comarmond⁵, Jacques Pouchot⁶, Michelle Rosenzwajg², David Klatzmann², Patrice Cacoub⁷ and David Saadoun⁸, ¹Hôpital Pitié-Salpêtrière, Internal Medicine and Clinical Immunology, Paris, France, ²GHPS, Paris, France, ³HEGP, Paris, France, ⁴I3 laboratory, Pitié-Salpétrière, Paris, France, ⁵DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ⁶Internal Medicine Department, European Hospital Georges Pompidou, Paris, France, ⁷Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, ⁸Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; INSERM, UMR_S 959, F-75013, Paris, France; CNRS, FRE3632, F-75005, Paris, France; AP-HP, Groupe Hospitalier, Paris, France
Background/Purpose: To compare microarray gene analysis of patients with Giant cell arteritis to patients with Takayasu arteritis. Methods: We performed comparative microarray gene analysis of…
Abstract Number: 790 • 2017 ACR/ARHP Annual Meeting
Pre-Clinical Evidences of Immunomodulatory Activities of Tuftsin-Phosphorylcholine on Samples from Patients with Giant Cell Arteritis in Comparison to Corticosteroids
Stefania Croci¹, Martina Bonacini¹, Francesco Muratore^2,3, Andrea Caruso³, Antonio Fontana⁴, Luigi Boiardi³, Alessandra Soriano^3,5, Alberto Cavazza⁶, Luca Cimino⁷, Lucia Belloni¹, Maria Parmeggiani¹, Miri Blank^8,9, Yehuda Shoenfeld^8,9 and Carlo Salvarani^2,3, ¹Unit of Clinical Immunology, Allergy and Advanced Biotechnologies, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, Reggio Emilia, Italy, ²University of Modena and Reggio Emilia, Italy, Modena, Italy, ³Unit of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, Reggio Emilia, Italy, ⁴Unit of Vascular Surgery, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, Reggio Emilia, Italy, ⁵Campus Bio-Medico, University of Rome, Italy, Roma, Italy, ⁶Unit of Pathology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, Reggio Emilia, Italy, ⁷Unit of Ocular Immunology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, Reggio Emilia, Italy, ⁸Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel, Ramat-Gan, Israel, ⁹Sackler Faculty of Medicine, Tel-Aviv University, Israel, Tel-Aviv, Israel
Background/Purpose: Tuftsin-PhosphorylCholine (TPC) is a novel bi-specific molecule which has shown immunomodulatory effects in experimental mouse models of lupus, colitis and arthritis but data in…
Abstract Number: 2932 • 2017 ACR/ARHP Annual Meeting
mTOR Pathway Is Activated in Endothelial Cells from Patients with Takayasu Arteritis and Is Modulated By Serum IgG
Jérôme Hadjadj¹, Guillaume Canaud², Tristan Mirault³, Maxime Samson⁴, Patrick Bruneval⁵, Alexis Regent⁶, Claire Goulvestre⁷, Veronique Witko-Sarsat⁸, Nathalie Costedoat-Chalumeau⁹, Loïc Guillevin for the French Vasculitis Study Group¹⁰, Luc Mouthon¹¹ and Benjamin Terrier¹², ¹Department of Internal Medicine, National Referral Center for Rare Autoimmune and Systemic Diseases, Hospital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Team Neutrophils and Vasculitis, INSERM U1016, Cochin Institute, Paris, France, Paris, France, ²Department of Nephrology and Transplantation, Necker-Enfants Malade, Université Paris Descartes, Sorbonne Paris Cité, INSERM U1151, Necker-Enfants Malades Hospital, Paris, France AP-HP, Paris, France, PARIS, France, ³Department of Vascular Medicine, Georges Pompidou European Hospital, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, Paris, France, ⁴Dijon University Hospital, Dijon, France, ⁵HEGP, Paris, France, ⁶National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁷Department of Immunology, Hospital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ⁸Team Neutrophils and Vasculitis, INSERM U1016, Cochin Institute, LABEX Inflamex, Université Sorbonne Paris Cité, 75013, Paris, France, Paris, France, ⁹Service de médecine interne Pôle médecine, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares de l’île de France, Paris, France, ¹⁰Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France, ¹¹Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France ;Université Paris Descartes Sorbonne Paris, Paris, France, ¹²Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France
Background/Purpose: Takayasu arteritis (TA) and giant cell arteritis (GCA) are large-vessel vasculitis characterized by vascular remodelling involving endothelial cells (ECs) and vascular smooth muscle cells,…
Abstract Number: 791 • 2017 ACR/ARHP Annual Meeting
Aortic Dilatation in Patients with Large Vessel Vasculitis: A Longitudinal Case Control Study Using Positron Emission Tomography/Computed Tomography
Filippo Crescentini¹, Francesco Muratore², Lucia Spaggiari³, Giulia Pazzola¹, Luigi Boiardi¹, Nicolò Pipitone¹ and Carlo Salvarani⁴, ¹Rheumatology Unit, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy, ²Rheumatology Unit, Arcispedale Santa Maria Nuova - IRCCS; Università di Modena e Reggio Emilia, Reggio Emilia, Italy, ³Radiology Unit, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy, ⁴Rheumatology Unit, Arcispedale Santa Maria Nuova - IRCCS; Università di Modena e Reggio Emilia, Reggio-Emilia, Italy
Background/Purpose: To evaluate aortic diameter and predictors of aortic dilatation using FDG-PET/CT in a longitudinally followed cohort of patients with large vessel vasculitis (LVV) compared…
Abstract Number: 793 • 2017 ACR/ARHP Annual Meeting
Metotrexate in the Treatment of Giant Cell Arteritis: To be or Not to be
Ignacio Castaño¹, Irene Monjo², Alejandro Balsa³, Diana Peiteado², Sara García-Carazo⁴ and Eugenio De Miguel¹, ¹Medicine, Universidad Autonoma Madrid, MADRID, Spain, ²Rheumatology, Hospital Universitario La Paz, MADRID, Spain, ³Rheumatology, Hospital La Paz-IdiPAZ, Madrid, Spain, ⁴Rheumatology, La Paz University Hospital, Madrid, Spain
Background/Purpose: The high-dose glucocorticoids (GCs) are the mainstay of treatment in Giant Cell Arteritis (GCA). Patients treated with greater GC dosages are at the greatest…
Abstract Number: 795 • 2017 ACR/ARHP Annual Meeting
Characteristics and Treatment Outcomes of Giant Cell Arteritis with Large-Vessel Lesions in a Nationwide, Retrospective Cohort Study in Japan
Takahiko Sugihara¹, Hitoshi Hasegawa², Haruhito Uchida³, Hajime Yoshifuji⁴, Yoshikazu Nakaoka⁵, Yoshiko Watanabe⁶, Eisuke Amiya⁷, Masanori Konishi⁸, Yasuhiro Katsumata⁹, Yoshinori Komagata¹⁰, Taio Naniwa^11,12, Takahiro Okazaki¹³, Yoshiya Tanaka¹⁴, Tsutomu Takeuchi¹⁵, Masayoshi Harigai¹⁶, Yoshihiro Arimura¹⁷ and Mitsuaki Isobe^8,18, ¹Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ²Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, Japan, ³Department of Chronic Kidney Disease and Cardiovascular Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ⁴Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁵Osaka University Graduate School of Medicine, Osaka, Japan, ⁶First Department of Physiology, Kawasaki Medical School, Kurashiki, Japan, ⁷Department of Cardiovascular Medicine, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ⁸Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan, ⁹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ¹⁰First Dept. of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan, ¹¹Division of Rheumatology, Dept of Internal Medicine,, Nagoya City University Hospital, Nagoya, Japan, ¹²Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ¹³Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ¹⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ¹⁶Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ¹⁷First Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan, ¹⁸Sakakibara Heart Institute, Tokyo, Japan
Background/Purpose: Giant cell arteritis (GCA) often affects aorta or its branches, but it is unclear whether the large-vessel (LV) lesions are associated with treatment outcomes.…
Abstract Number: 796 • 2017 ACR/ARHP Annual Meeting
Presentation and Outcome of Large-Vessel Vasculitis Diagnosed between 50 and 60 Years: Case-Control Study Based on 183 Cases
Laure Delaval^1,2, Aurélie Daumas³, Maxime Samson⁴, Mikael Ebbo⁵, Hubert de Boysson⁶, Eric Liozon⁷, Henry Dupuy⁸, Alexis Regent⁹, Mathieu Puyade¹⁰, Daniel Blockmans¹¹, Estibaliz Lazaro¹², Ygal Benhamou¹³, Karim Sacre¹⁴, Alice Bérezné¹⁵, Loïc Guillevin^2,9,16 and Benjamin Terrier^17,18,19, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, paris, France, ²Internal medicine, Cochin University Hospital, paris, France, ³Department of Internal Medicine, Aix-Marseille Université, La Timone University Hospital, AP-HM, Marseille, France, ⁴Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ⁵internal medicine, Aix-Marseille Université, La Timone University Hospital, AP-HM, Paris, France, ⁶Department of Internal Medicine, Caen University Hospital, Caen, France, ⁷Departement of Internal Medicine, Limoges University Hospital, Limoges, France, ⁸Department of Internal Medicine, Haut-Lévêque Hospital, Pessac, France, ⁹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ¹⁰Department of Internal Medicine, University Hospital of Poitiers, Poitiers, France, ¹¹General Internal Medicine, University Hospital Gasthuisberg, Leuven, Belgium, ¹²Department of Internal Medecine and Clinical Immunology, Bordeaux University Hospital, Pessac, France, ¹³Department of internal medicine, University Hospital of Rouen, Rouen, France, ¹⁴Department of Internal Medicine, Bichat Hospital, Paris, France, ¹⁵Department of internal medicine, CHR Annecy-Genevois, Metz-Tessy, France, ¹⁶French Vasculitis Study Group (FVSG), Paris, France, ¹⁷Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ¹⁸Internal Medicine, Cochin University Hospital, Paris, France, ¹⁹French Vasculitis Study Group (FVSG), paris, France
Background/Purpose: Primary large-vessel vasculitis (LVV) include giant cell arteritis (GCA) and Takayasu arteritis (TA). Age at onset is commonly used to distinguish GCA and TA.…
Abstract Number: 797 • 2017 ACR/ARHP Annual Meeting
Temporal Arteritis Revealing Antineutrophil Cytoplasmic Antibody–Associated Vasculitides: A Retrospective Study of 50 Cases
Laure Delaval^1,2, Maxime Samson³, Flora Schein⁴, Christian Agard⁵, Olivier Aumaître⁶, Alban Deroux⁷, Henry Dupuy⁸, Cyril Garrouste⁹, cedric landron¹⁰, Francois Maurier¹¹, Pascal Cathebras¹², Loïc Guillevin^2,13,14 and Benjamin Terrier^15,16,17, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, paris, France, ²Internal medicine, Cochin University Hospital, paris, France, ³Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ⁴Internal medicine, University Hospital St Etienne, Saint Etienne, France, ⁵Internal Medicine Department, Nantes University Hospital, Nantes, France, ⁶CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, ⁷Internal Medicine, CHU de Grenoble, Grenoble, France, ⁸Department of Internal Medicine, Haut-Lévêque Hospital, Pessac, France, ⁹Nephrology, CHU, Clermont-Ferrand, France, ¹⁰service de médecine interne, CH Poitiers, CHU Poitiers, poitiers, France, ¹¹Internal Medicine, Sainte-Blandine de Metz Hospital, Metz, France, ¹²Internal Medicine, University Hospital St Etienne, St Etienne, France, ¹³French Vasculitis Study Group (FVSG), Paris, France, ¹⁴National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ¹⁵Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ¹⁶French Vasculitis Study Group (FVSG), paris, France, ¹⁷Internal Medicine, Cochin University Hospital, Paris, France
Background/Purpose: Giant cell arteritis (GCA) is a non-necrotizing granulomatous arteritis involving large vessels, whereas antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitides (AAV) are a group of necrotizing…
Abstract Number: 259 • 2017 ACR/ARHP Annual Meeting
Imaging for Diagnosis, Monitoring and Outcome Prediction of Large Vessel Vasculitis: A Systematic Review of the Literature and Meta-Analysis Informing the EULAR Recommendations
Christina Duftner¹, Christian Dejaco², Alexandre Sepriano³, Louise Falzon⁴, Wolfgang A. Schmidt⁵ and Sofia Ramiro⁶, ¹Department of Internal Medicine, Clinical Division of Internal Medicine II, Medical University Innsbruck, Innsbruck, Austria, ²Rheumatology, Hospital of Bruneck, Bruneck, Italy, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Center for Behavioral Cardiovascular Health, Columbia University Medical Center, New York, NY, ⁵Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, ⁶Rheumatology, Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands
Background/Purpose: Modern imaging techniques including ultrasound (US), magnetic resonance imaging (MRI), computed tomography (CT) and 18F-FDG positron emission tomography (PET) are increasingly studied in large…
Abstract Number: 799 • 2017 ACR/ARHP Annual Meeting
Acetylcholinesterase Is Highly Expressed in the Inflamed Vessel Wall of Patients with Giant Cell Arteritis
Philip Therkildsen¹, Berit Dalsgaard Nielsen¹, Kresten Krarup Keller², Torben Steiniche³, Lars Christian Gormsen⁴, Ib Tønder Hansen⁵ and Ellen-Margrete Hauge⁶, ¹Department of Rheumatology, Aarhus University Hospital, Aarhus C, Denmark, ²Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Department of Histopathology, Aarhus University Hospital, Aarhus C, Denmark, ⁴Nuclear Medicine and PET Center, Department of Nuclear Medicine and PET Center, Aarhus University Hospital, Århus C, Denmark, ⁵Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁶Department of Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: The temporal artery biopsy (TAB) remains the gold standard in the diagnosis of giant cell arteritis (GCA). However, TABs are false-negative in 40% of…
Abstract Number: 261 • 2017 ACR/ARHP Annual Meeting
Ultrasound CUT-Off in GIANT CELL Arteritis a Solution to Arteriosclerosis Pitfall in the Halo Sign
Eugenio De Miguel¹, Luis M Beltran², Irene Monjo², Francesco Deodati², Wolfgang A. Schmidt³ and Juan García-Puig², ¹Rheumatology, University Hospital La Paz, IdiPaz, Madrid, Spain, ²Internal Medicine, Hospital Universitario La Paz, MADRID, Spain, ³Immanuel Krankenhaus Berlin, Med Ctr for Rheumatology Berlin-Buch, Berlin, Germany
Background/Purpose: At the age of Giant Cell Arteritis (GCA) atherosclerosis is common. The ultrasonographic (US) appearance of athermanous plaque is usually easily differentiated from the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].